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Vitamin D is synthesized in the skin following exposure to UVB radiation or is directly
absorbed from the diet. Following hydroxylation in the liver and kidneys, vitamin D
becomes its bioactive form, 1,25(OH)2D, which has been described to have potent
immunomodulatory capacity. This review will focus on the effect of vitamin D in modulating
the dysregulated immune system of autoimmune rheumatic diseases (ARD) patients
across age, in particular in arthritis (rheumatoid arthritis and juvenile idiopathic arthritis),
and systemic lupus erythematosus (with adult and juvenile onset). As well as delineating
the impact of vitamin D on the innate and adaptive immune functions associated with each
disease pathology, this review will also summarize and evaluate studies that link vitamin D
status with disease prevalence, and supplementation studies that examine the potential
benefits of vitamin D on disease outcomes. Exploring this evidence reveals that better
designed randomized controlled studies are required to clarify the impact of vitamin D
supplementation on ARD outcomes and general health. Considering the accessibility and
affordability of vitamin D as a therapeutic option, there is a major unmet need for evidence-
based treatment recommendations for the use of vitamin D in this patient population.
Keywords: vitamin D, rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus,
immunomodulatory, autoimmunityINTRODUCTION
Vitamin D is an essential micronutrient synthesized in the body or obtained from the diet. In recent
decades, vitamin D deficiency (< 50 nmol/L) and insufficiency (50–75 nmol/L) has emerged as a
widespread health problem (Table 1) (1, 2). According to available evidence, less than 50% of the
global population have adequate vitamin D levels in their blood (3). The predominant bioactiveorg February 2021 | Volume 11 | Article 6164831
Zou et al. Vitamin D Immunomodulation in ARDsform of vitamin D is cholecalciferol (vitamin D3), which is
synthesized in the skin from 7-dehydrocholesterol following
exposure to sunlight (UVB radiation). Other forms of vitamin
D (mainly as ergocalciferol or vitamin D2) can also be absorbed
from various foods e.g., oily fish, red meat, liver, egg yolks,
fortified cereals, and specific supplements e.g., fish oil. Both
cholecalciferol and ergocalciferol are converted via a two-step
activation process (Figure 1). Firstly, cholecalciferol and
ergocalciferol are hydroxylated in the liver and converted into
the inactive metabolites 25-hydroxyvitamin D [25(OH)D3
(calcifediol) and 25(OH)D2 (ercalcidiol)], respectively.
Secondly, calcifediol and ercalcidiol are hydroxylated to the
bioactive form 1,25(OH)2D3 (calcitriol) and 1,25(OH)2D2
(ercalcitriol), respectively, in the kidneys. Much like other
steroid hormones, both calcitriol and ercalcitriol bind to the
vitamin D receptors (VDR) within cells, albeit ercalcitriol with a
much lower affinity. VDR then heterodimerise with retinoid X
receptors (RXR) and the complex translocates into the nucleus
(4). This heterodimer in turn binds to vitamin D receptor
elements (VDRE) present in various cell genes, altering gene
expression (4). Two types of vitamin D supplementation are
available, vitamin D2 and D3.
The classical role of bioactive vitamin D is to promote
intestinal and renal calcium absorption, maintaining a very
precise regulation of calcium transfer between bones and blood
stream. Positive calcium balance is characterized by net bone
formation, either as bone growth or repair; while in negative
calcium balance, vitamin D promotes bone resorption and
inhibits bone mineralization to maintain serum calcium levels
(5). As a consequence, vitamin D has an active role in the
prevention of bone fractures associated with low bone density/
osteoporosis, eliciting fracture reduction effect from a minimum
serum concentration of 74 nmol/L, which is now widely accepted
as lower limit of optimal vitamin D level (Table 1) (6). Following
the observation that VDRs are also expressed by immune cells,
endothelial cells, and vascular smooth muscle cells (7–9), there is
now a wealth of studies demonstrating that vitamin D has anAbbreviations: ANA, Anti-nuclear Antibodies; ARD, Autoimmune Rheumatic
Diseases; CCP, anti-Cyclic Citrullinated Peptide; CD4, cluster of differentiation 4;
DMARD, disease-modifying anti-rheumatic drug; DAS28, Disease Activity Score-
28; ECLAM, European Consensus Lupus Activity Measurement; ESR, Erythrocyte
Sedimentation Rate; HLA, Human Leukocyte Antigen; JADAS, Juvenile Arthritis
Disease Activity Score; JIA, Juvenile Idiopathic Arthritis; JSLE, Juvenile Systemic
Lupus Erythematosus; MMP, Matrix Metalloprotease; NSAID, Nonsteroidal anti-
inflammatory drug; OPG, Osteoprotegerin; RA, Rheumatoid Arthritis; RANKL,
Receptor Activator of Nuclear factor Kappa-B Ligand; RCT, Randomized
Controlled Trial; RF, Rheumatoid Factor; RXR, Retinoid X Receptor; SLE,
Systemic Lupus Erythematosus; SLEDAI, SLE disease activity index; Th, T
helper; VAS, Visual Analogue Scale; VDR, Vitamin D Receptor; VDRE,
Vitamin D Receptor Elements; UCTD, undifferentiated connective tissue disease.
Frontiers in Immunology | www.frontiersin.org 2additional immunomodulatory role, as well as implications in
cardio-vascular health. Recent research has linked vitamin D
deficiency to the pathogenesis of various immune-mediated
inflammatory diseases in both children and adults (10, 11),
Importantly, there is some evidence that vitamin D deficiency
may act as an environmental trigger for autoimmune disease
development (12, 13), and in particular autoimmune rheumatic
diseases (ARD) (14, 15), with some studies suggesting that there
may be some therapeutic benefit of vitamin D supplementation
in these diseases (13, 16).
In this review, we will discuss the evidence for an
immunomodulatory effect of vitamin D on the two of the most
prototypical ARD across age; rheumatoid arthritis (RA) and
juvenile idiopathic arthritis (JIA) and juvenile and adult-onset
systemic lupus erythematosus (SLE). Although, exploring the
immunomodulatory role of vitamin D in the process of
atherosclerosis which is a common co-morbidity associated with
chronic inflammation as seen in various ARDs is beyond the scope
of this review, it is worth mentioning the protective effects of
vitamin D on endothelial activation and dysfunction, through
inhibition of cyclooxygenase 2 and cellular/platelets adhesion
molecules expression, as well as pro-inflammatory cytokines
synthesis, therefore minimizing the inflammatory processes
contributing to atherosclerosis plaque formation (17, 18).IMMUNE DYSREGULATION IN
RHEUMATOID ARTHRITIS AND JUVENILE
IDIOPATHIC ARTHRITIS
Although RA and JIA are completely different diseases, they are
both characterized by immune-mediated joint inflammation. In
both diseases, autoimmune arthritis is characterized by
inflammation of the synovial membrane, which involves the
proliferation of synoviocytes and invasion of inflammatory
immune cells into the synovium. This leads to synovial
membrane thickening, which, if left untreated, ultimately leads
to irreversible articular cartilage destruction and bone erosions
(19). In adults, RA is one of the most common chronic rheumatic
diseases, affecting 0.5–1% of the global population (20). In
children, autoimmune inflammatory arthritis is classified under
the umbrella term of JIA and is also one of the most common
rheumatic diseases in children and adolescents. JIA terminology
encompasses many types of arthritis, which are pathologically
distinct from RA with the exception of the rheumatoid factor
(RF) positive polyarticular JIA phenotype, present in less than
10% JIA patients which is clinically, serologically and genetically
similar to the RA phenotype in adults (21, 22). For simplicity, in
this review, we will focus on studies in patients with oligo-
articular JIA (oligo-JIA), which is the most common phenotype
in children, and polyarticular-JIA (poly-JIA), where, as described
above, there is some overlap with the pathogenesis of RA (23).
Disease activity in RA is measured by using the Disease Activity
Score-28 (DAS28) index, which includes swollen and tender
joint counts out of 28 designated joints, ESR or CRP levels, and
subjective rating of global health measured on a 1–10 visualTABLE 1 | Definition of vitamin D status. 1 nmol/L = 0.4 ng/mL.
Vitamin D status Concentration of serum 25(OH)D
Vitamin D deficiency <50 nmol/L
Vitamin D insufficiency 50–75 nmol/L
Vitamin D sufficiency >75 nmol/LFebruary 2021 | Volume 11 | Article 616483
Zou et al. Vitamin D Immunomodulation in ARDsanalogue scale (VAS). For JIA, the most used disease activity
measure is the Juvenile Arthritis Disease Activity Score (JADAS),
which assesses a variable number of joints (10, 27, or 77), as well
as physician and patient/parent VAS rating of disease activity
and inflammation (ESR).Frontiers in Immunology | www.frontiersin.org 3Although fundamentally different diseases, oligo-JIA, poly-JIA,
and RA share many immunopathogenic features that lead to
synovitis, including being characterized by a strong pro-
inflammatory cytokine signature. Activated myeloid cells
produce increased levels of TNF-a, IL-6, IL-1b at the inflamedFIGURE 1 | Vitamin D (both D3 and D2) metabolic pathway and its physiological impact on immune cells. D3 is synthesized from either 7-dehydrocholesterol from
the skin via UVB activation or through the diet. D2 is obtained from the diet. CYP2R1 enzyme converts D3/D2 to 25(OH)D3/D2 in the liver. CYP27B1 transforms 25
(OH)D3/D2 into 1,25(OH)2D3/D2 in the kidneys. 1,25(OH)2D binds to VDR in immune cells which then bind to VDRE on genes to change gene expression. 1,25(OH)2D can
inhibit dendritic cell maturation, promote monocyte proliferation and differentiation into macrophages. It can also increase anti-inflammatory cytokines and the frequency of
Tregs, as well as reduce pro-inflammatory Th1 cytokines. 1,25(OH)2D can also reduce the ratio of CD4/CD8 and inhibit pro-inflammatory T cell differentiation and suppress
antibody production by B cells.February 2021 | Volume 11 | Article 616483
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blocking these cytokines in both RA and JIA (24–26). There is also
an imbalance of T-helper 1 (Th1) and T-helper 17 (Th17) cells
compared to T helper 2 (Th2) and regulatory T (Treg cells) (27),
and both RA and JIA have been postulated to be mediated by both
the type 1 cytokines such as IFN-g produced and IL-17 (28).
Collectively, TNF-a, IL-6, IL-1b, and IL-17 form positive feedback
loops increasing the production of these potent inflammatory
cytokines, promoting synovial inflammation, and bone resorption,
which characterize both diseases. Additionally, in both diseases, B
cells secrete autoantibodies, such as rheumatoid factors (RF), anti-
cyclic citrullinated peptide (CCP) antibodies, and, in some oligo-
JIA and poly-JIA patients, anti-nuclear antibodies (ANAs) (29,
30). B cells can also contribute to inflammation by producing
chemokines and cytokines that trigger inflammation and synovial
hyperplasia, and by presenting autoantigens to autoreactive T cells
(31). It is thought that a complex interplay between genetic and
environmental factors leads to this breakdown in immunological
tolerance and thus synovial inflammation. Variants within HLA
genes have been demonstrated to increase the risk of developing
RA and JIA (32, 33), whilst environmental factors such as
exposure to tobacco smoke and changes to the gut microbiota
have been implicated in disease development (34, 35). In recent
years, new evidence has emerged that vitamin D deficiency and
insufficiency may also be an important environmental trigger in
the onset of disease.PREVALENCE OF HYPOVITAMINOSIS D
AND ITS IMPACT ON THE RISK OF
DEVELOPING RHEUMATOID ARTHRITIS
AND JUVENILE IDIOPATHIC ARTHRITIS
Numerous studies have investigated the relationship between
vitamin D insufficiency/deficiency and autoimmune arthritis,
establishing that RA patients present with lower vitamin D levels
than healthy controls (36–39). A systematic review with 3,489
people from 24 reports found that RA patients had lower 25(OH)D
levels than healthy controls with a mean difference of 16.52 nmol/L
(= 6.6 ng/ml) (38). Likewise, the COMORA study measured
vitamin D levels of 1,413 RA patients from 15 countries and
reported that 63% of patients were either vitamin D insufficient or
deficient (36). Similarly, in JIA patients, the evidence for
hypovitaminosis D, or low vitamin D levels, is consistent across
several studies (40–43). A scoping review in 2018 reported that 32/
38 studies showed a high prevalence (84.2%) of suboptimal 25(OH)
D levels (< 30ng/ml) in JIA patients (41). Similarly, a meta-analysis
revealed widespread vitamin D deficiency status in JIA patients (up
to 82%) (42). These data strongly suggest that children and adults
with inflammatory arthritis have low concentrations of circulating
vitamin D.
Another important consideration is whether individuals with
low vitamin D levels are at risk for developing arthritis. There is
controversial evidence regarding the impact of vitamin D intake
on the risk of developing RA. The Iowa Women’s Health StudyFrontiers in Immunology | www.frontiersin.org 4recorded the vitamin D intake of 29,368 women without RA at
baseline with a self-reported questionnaire and followed them
through 11 years (44). They found a negative correlation between
vitamin D intake and RA risk (relative risk RR = 0.72).
Conversely, the Nurses’ Health Study reported no relationship
between vitamin D intake and risk of RA (45). Yet, interestingly,
a meta-analysis of the Iowa and NHS cohorts found an overall
significant relationship between RA risk and total vitamin D
intake (diet and supplements) (RR = 0.758, p = 0.047) (46).
Patients with the lowest vitamin D intake had a 24.2% higher risk
of RA than those with the highest vitamin D intake. Together,
these studies indicate that it is challenging to get an accurate
picture of vitamin D intake and RA risk. This brings into
question the validity of dietary intake assessments with food
frequency questionnaires without measuring serum vitamin D
levels. Limitations of these questionnaires include reporting bias
and their closed and limited format. There are no similar studies
for JIA.VITAMIN D LEVELS AND DISEASE
ACTIVITY: THERAPEUTIC IMPLICATIONS
FOR RHEUMATOID ARTHRITIS AND
JUVENILE IDIOPATHIC ARTHRITIS
Considering the evidence that both JIA and RA patients have low
vitamin D levels, there is growing interest in understanding
whether altering vitamin D levels can impact disease activity.
For RA, most studies have concluded that serum 25(OH)D levels
inversely correlated with the DAS28 index (36–38, 46) (Table 2).
From the limited studies available in JIA, it remains controversial
whether 25(OH)D levels correlate with disease activity. However, a
number of studies found negative correlations between JIA disease
activity and serum 25(OH)D levels, although it remains difficult to
infer a causal relationship (43, 50, 51), as the majority of studies
were cross-sectional. No causal relationship between vitamin D
levels and disease activity can be inferred as the evidence from
randomized controlled trials (RCTs) is lacking. The evidence for a
link between vitamin D supplementation and RA disease activity is
inconsistent. Some studies suggested a decrease in DAS28
following supplementation, whereas other studies reported no
significant change in DAS28 or flare rate after supplementation
(Table 3). Due to the variation in the type of vitamin D
supplementation, dose, and duration, it is extremely difficult to
compare these studies. The majority of studies supplemented
vitamin D deficient patients only (52–55); two studies
supplemented patients irrespective of serum levels (57), though
in one study, 90% of the patients were vitamin D insufficient (58).
For JIA, only one cross-sectional study has investigated the role of
vitamin D supplementation in modulating disease activity and did
not report any therapeutic benefits (58). Standardizing the method
and amount of supplementation would allow more comparison
across different studies and cohorts. Further studies are needed to
clarify whether vitamin D has any therapeutic benefits for in RA
or JIA.February 2021 | Volume 11 | Article 616483
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FOR VITAMIN D IN RHEUMATOID
ARTHRITIS AND JUVENILE
IDIOPATHIC ARTHRITIS
There are several mechanisms by which vitamin D could modify
inflammatory pathways in autoimmune inflammatory arthritis
(Figure 2). For example, 1,25(OH)2D3 can influence myeloid-
derived cytokine pathways. An in vitro study demonstrated that
the exposure of RA fibroblast-like synviocytes to 1,25(OH)2D3 (in
doses ranging from 0.1 to 100 nM, therefore equivalent to sub-
physiological and optimal vitamin D serum concentrations)
decreased TNF-a and IL-6 expression and at the same time,
reduced osteoclastogenic RANKL (receptor activator of nuclear
factor kappa-B ligand) levels relative to OPG (osteoprotegerin), an
inhibitor of RANKL activity (59). In vivo, 1,25(OH)2D3 treatmentFrontiers in Immunology | www.frontiersin.org 5at supra-physiological concentration (1 mmol/L) inhibited
synoviocyte invasion and reduced IL-1b and matrix
metalloprotease-1 (MMP-1) when measured ex vivo (60).
Although the mechanism by which this suppression of cytokine
production by synoviocytes remains unknown, 1,25(OH)2D3 was
detected in the arthritic synovium and VDRs were found in
rheumatoid synovial tissue suggesting that there may be direct
suppression of cytokine gene expression in these cells (61).
Interestingly, it has been suggested that 1,25(OH)2D3 can only act
as negative feedback to reduce inflammatory responses when the
immune system is activated (62), in which 1,25(OH)2D3 can
promote synoviocyte apoptosis but only in the presence of TNF-
a (63).
1,25(OH)2D3 can also alter T cell differentiation by promoting
a shift of Th cells from Th1/Th17 profile (64, 65), which is
pathogenic in both RA and JIA, to a Th2/Treg, profile, associated
with anti-inflammatory properties (66). 1,25(OH)2D3 stimulatesTABLE 2 | Impact of vitamin D concentration on RA and JIA outcomes.
Author et al., year Country Type of study Number of
participants,F:M Age
Disease duration Impact on disease outcomes
RA
Hajjaj-Hassouni et al., 2017
(COMORA study) (36)
Asia, Europe, North America,
South America, Africa





8.3 (3.6–15.2) years Serum 25(OH)D levels and DAS28 were inversely
correlated (r = -0.104; p < 0.001)
Lin et al., 2016 (38) Asia, Europe, North America,
South America, Africa, 24
studies
Systematic review and meta-
analysis
3,489 N/A Serum 25(OH)D levels and DAS28 were inversely
correlated (r = -0.13; p = 0.02).
Song et al., 2012 (46) Europe, North America,
Middle East





N/A 7 out of 8 studies reported an inverse relationship
between vitamin D levels and DAS28
Lee and Bae, 2016 (37) Asia, Europe, South America,
Africa
15 Case-control studies
924 RA patients N/A Inverse correlation between vitamin D levels and DAS28
(r = -0.278, p < 0.001)





12 (1–37) years No significant correlation between vitamin D levels and
DAS28 with or without GVAS.
Significant inverse correlation between vitamin D levels
and VAS-pain (r = -0.249, p = 0.013)









No correlation between vitamin D levels and DAS28.
JIA





28 (6–66) months No correlation between 25(OH)D levels and JADAS27
JADAS27 was higher in polyarticular JIA than
oligoarticular JIA (p = 0.003)







Patients with active disease and frequent relapses have
significantly lower 25(OH)D levels than those without (p <
0.005)





28 months Negative correlation between 25(OH)D levels and disease
activity (r = -0.37, p = 0.01)
JADAS27 is greater in patients with 25(OH)D levels <15








4.1 ± 1.1 years A significant relationship between vitamin D level and
number of active joints.DAS28, disease activity score assessing 28 joints; JADAS 27, juvenile arthritis disease activity score assessing 27 joints; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; VAS,
visual analogue scale; N/A, not available; 25(OH)D, 25-hydroxy vitamin D.February 2021 | Volume 11 | Article 616483
Zou et al. Vitamin D Immunomodulation in ARDsthe expressionof both IL-10+ andFoxp3+Treg cells in humanTcell
culture (67, 68). 1,25(OH)2D3 inhibited cytokines essential for
Th1 and Th17 maturation (66) and upregulated the expression of
transcription factors that induce Th2 cell development (69).
Interestingly, in RA patients, serum 25(OH)D level was inversely
correlated with IL-17 levels (70) and in vitro physiological doses of
1,25(OH)2D3 have been shown to decrease the IL-17 production by
Th17 cells (71). Considering these complementary actions of
immunosuppression, it has been suggested that that vitamin D
may be more efficacious at suppressing immunological pathogenic
mechanism when acting as an adjunct therapy. For example, Kim
et al. found that 25(OH)D sufficient RApatients had greaterDAS28
reduction in response to tocilizumab treatment (an IL-6 receptor
antagonist) than 25(OH)D deficient patients and the difference
persisted for 48weeks (72).This study also showed that the addition
of tocilizumab and 1,25(OH)2D3 in vitro suppressed the IL-17
production synergistically (72).A significant limitationof this study
was that only baseline 25(OH)D level was recorded; it did not
account for any changes in 25(OH)D levels in patients throughout
the follow-up period. Furthermore, in vitro, 1,25(OH)2D3 at an
optimal physiological concentration in combination with
corticosteroids additively inhibited the TNF-a, IL-17, IL-6, and
matrix metallopeptidase (MMP) production by synoviocytes co-
cultured with T-cells (73). Notably, TNF-a could only be inhibited
by the combination of both 1,25(OH)2D3 and corticosteroid andFrontiers in Immunology | www.frontiersin.org 6not by either alone, suggesting that vitaminDwas beneficial only in
combination with corticosteroid exposure. Although these in vitro
experimental setting cannot replicate the pathological synovial
environment of RA or JIA, they do provide evidence that vitamin
D supplementation could be more efficacious at suppressing
inflammatory mediators when given in combination with other
therapeutic agents.
It is important to note that one study argued against the use of
1,25(OH)2D3 to treat active RA, by demonstrating that there was
a difference in the effect of optimal physiological 1,25(OH)2D3
concentration on Th17 in serum compared to those in the
synovial fluid (74). The authors proposed that 1,25(OH)2D3
had a lower inhibitory effect on Th17 in the synovial fluid
because 1,25(OH)2D3 is less effective on the more committed T
cell phenotypes present in the synovium compared to the naïve T
cells in the serum. Thus, they questioned the efficacy of vitamin
D as a potential treatment for active RA patients; rather, they
proposed it can be used as a prophylactic measure to reduce the
recurrence of flares in patients in remission. Future studies
should investigate the reason behind the lack of synovial
response to 1,25(OH)2D3 and explore ways to improve its
sensitivity. At the same time, supplementation studies should
be conducted in subjects at risk of RA or in the early stages of RA
to explore vitamin D role in preventing abnormal immune
activation (62).TABLE 3 | Impact of vitamin D supplementation on RA and JIA outcomes.
Author et al.,
year
Country Type of study
Study duration
Number of patients vs. control
group (if any) F:M, Age
(mean +/- SD)











60,000 IU/week for 6 weeks
then 60,000 IU/month for 1
month
Mean DAS28-CRP decreased significantly: 3.68 ±






40 patients in the intervention
arm vs. 40 in the placebo arm;
7:1
45 ± 8.66 vs. 42.7 ± 9.77 for
case and control groups,
50,000 IU/week No significant difference in DAS28 between
intervention and placebo group.
No significant difference in flare rate between






64 case group vs 88 control
6.8:1
44.2 ± 7.5 vs. 41.7 ± 8.6
Alfacalcidol
0.5 µg/day
No significant difference in disease recurrence







11 patients in the intervention
arm vs. 11 in the placebo arm
0.83:1
63 ± 12 vs. 53 ± 11
Ergocalciferol
50,000 IU*3/week for 4 weeks,
then 50,000 IU*2/month for 11
months







240 patients in the intervention
arm vs. 410 patients in placebo
arm










100,000 IU/month vit D3 Significantly decreased DAS28 scores in patients
with 25(OH)D ≥20 ng/ml (p < 0.01) after 3 months.
No significant decrease in patients with 25(OH)D
<20 ng/ml after 3 months
JIA






18 patients in the intervention
arm vs. 18 in the control arm
1.8:1
7.6 ± 4.3 vs 6.3 ± 2.9
2,000 IU/day vit D3 No significant decrease in disease activityDAS28, disease activity score assessing 28 joints; DAS28-CRP, disease activity score assessing 28 joints including C-reactive protein as inflammatory marker; JIA, juvenile idiopathic
arthritis; RA, rheumatoid arthritis; RCT, randomized controlled trial; 25(OH)D, 25-hydroxy vitamin D.February 2021 | Volume 11 | Article 616483




SLE is a severe autoimmune rheumatic disease that is
characterized by chronic, multisystem inflammation (75). It
has an unpredictable course, with disease flares alternating
with periods of clinical remission (76). The disease is more
prevalent in females than males and peaks at the time of
puberty in girls. SLE occurs most commonly in patients of 15–
44 years of age, although 15–20% of cases start in childhood or
adolescence (in which case the disease is called juvenile SLE-Frontiers in Immunology | www.frontiersin.org 7JSLE) (77, 78). JSLE can often be more severe, involving life-
threatening damage to the kidneys and central nervous system.
SLE patients overall require long term and aggressive treatments,
and the mortality is increased in JSLE compared with adult-onset
SLE. The primary diagnosis for SLE and JSLE is made using a
combination of characteristic clinical features and detection of
autoimmune antibodies, such as ANA, and in particular,
antibodies against double-stranded DNA (dsDNA) which are
specific for SLE (79). In clinical settings and experimental
studies, SLE disease activity is measured using the SLE disease
activity index (SLEDAI) which is a global index comprising 24
clinical and laboratory variables (80).
SLE is primarily thought of as a type 1 IFN driven disease.
Both JSLE and SLE patients have an increased IFN signature,FIGURE 2 | Pathogenesis of RA/JIA and mechanisms of vitamin D acting on immune cells. A breakdown in tolerance in RA/JIA leads to increased Th1/Th17 cells
and promotes macrophages to produce pro-inflammatory cytokines (IL-1b, IL-17, IL-6, TNF-a) which in turn stimulates fibroblast synoviocyte proliferation.
Synoviocytes then activate osteoclasts and secrete MMPs which break down bone and cartilage. Vitamin D shifts the balance of Th cells from Th1/Th17 to Th2/Treg,
inhibit B cells and autoantibody production, reduces pro-inflammatory cytokines, and inhibits synoviocyte proliferation. MMP, matrix metallopeptidase.February 2021 | Volume 11 | Article 616483
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and lymphocytes, when compared to healthy controls (81, 82). It
is thought that endogenous nucleic acids released by apoptotic
cells or historic viral infections lead to the production of IFN-a
by plasmacytoid dendritic cells. IFN-a goes on to activate
autoreactive B cells, T helper (Th) cells and cytotoxic T cells.
These endogenous nucleic acids and apoptotic cells are then
bound by anti-nuclear autoantibodies (ANAs), leading to
immune complex deposition and epitope spreading. Self-
antigens are also presented by mature dendritic cells (non-
tolerogenic) (83, 84), which activate pro-inflammatory Th cells
(83). Similarly to RA, HLA genetic variants and complement
genes have been associated with SLE (85). Environmental factors
such as UV light, Epstein-Barr virus infection and obesity could
contribute to SLE predisposition. A key feature of lupus is the
skin photosensitivity, which leads to many SLE patients avoiding
exposure to sunlight, it is perhaps unsurprising that low vitamin
D levels have been described in many lupus patients.PREVALENCE OF HYPOVITAMINOSIS D
AND ITS IMPACT ON THE RISK OF
DEVELOPING JSLE AND ADULT-ONSET
SYSTEMIC LUPUS ERYTHEMATOSUS
The evidence for inadequate vitamin D levels in SLE is well
documented. Recently, a systematic review further confirmed the
high prevalence of vitamin D insufficiency in SLE (86). It
evaluated 34 case-control studies consisting of 2265 SLE
patients and concluded that serum 25(OH)D levels were
significantly lower in SLE patients than controls (p < 0.00001).
Other cross-sectional studies across Europe, South America, and
Asia have reached similar conclusions that the overwhelming
majority of SLE patients had insufficient vitamin D levels, which
were significantly lower than healthy controls (87–89). As
described above, the prevalence of hypovitaminosis D in SLE
patients is likely due to the precautions taken by the patients to
avoid the sun because of skin photosensitivity, with one study
confirming that photosensitivity and photoprotection predicted
vitamin D insufficiency and deficiency respectively (87). The use
of corticosteroids and antimalarials for SLE treatment can also
contribute to reduced vitamin D levels by inhibiting intestinal
absorption of cholecalciferol and promoting vitamin D
catabolism (90–92). Despite a paucity of studies on JSLE, the
existing studies show similar results to adult SLE studies (93–96).
Like the adult disease, vitamin D deficiency is prevalent in JSLE
patients. This was shown in the APPLE trial which found that
69% of 201 JSLE patients had vitamin D insufficiency and 30%
had vitamin D deficiency (93).
As for the relationship between dietary intake and SLE risk,
the Nurses’ Health Study (NHS), a prospective cohort study with
186,389 women follow-up for 22 years, reported no relationship
between vitamin D intake and risk of SLE (45). Nor was intake in
adolescence related to SLE risk in adulthood (97). Similarly,
Lourdudoss et al. did not find any protective effect of dietaryFrontiers in Immunology | www.frontiersin.org 8vitamin D intake on lupus activity in 111 SLE patients during a 2-
year period (98).VITAMIN D LEVELS AND DISEASE
ACTIVITY: THERAPEUTIC IMPLICATIONS
FOR SLE AND JSLE
As with RA, a number of studies have reported an inverse
association between serum 25(OH)D levels and disease activity
as measured by the SLEDAI score in the majority of studies, and
also by the European Consensus Lupus Activity Measurement –
ECLAM score, in one study (99). They are summarized in Table
4. In JSLE, one study has also reported a potential inverse
relationship between disease activity and 25(OH)D levels (94).
Notably, approximately 81% of adult SLE patients also present
with fatigue, which remains one of the most troublesome and
common symptoms in SLE patients and is inadequately
addressed by current treatment strategies (103). Thus, it is
important to highlight that two studies have suggested a
potentially inverse association between 25(OH)D levels and
fatigue scores (87, 102) (Table 4). Like RA, most studies were
cross-sectional, thus only correlations were inferred. A causal
relationship remains undetermined. Importantly, these studies
were conducted in different countries around the world, but all
reached the same conclusion which shows that hypovitaminosis
D in SLE patients is prevalent. This suggests that changes to
geographical sunlight levels does not influence these results.
Regarding the investigation of the vitamin D supplementation
role in SLE, most studies reported no significant improvements
in disease activity (Table 5). Only one study reported a reduced
risk of achieving a moderately-high SLEDAI score (≥ 5) after
vitamin D supplementation (106). On the other hand, two JSLE
demonstrated decreases in disease activity after supplementation
(Table 5). Notably, most studies either solely or mainly
supplemented vitamin D insufficient patients (95, 105–109).
Two studies treated both vitamin D insufficient and sufficient
patients (96, 104).IMMUNOMODULATORY MECHANISMS
OF VITAMIN D IN SYSTEMIC LUPUS
ERYTHEMATOSUS AND JSLE
Vitamin D has been demonstrated to influence many
immunological pathways that contribute to SLE pathogenesis
(Figure 3). For example, 1,25(OH)2D3 has been demonstrated to
inhibit of dendritic cell maturation. In one seminal study, VDR
knockout mice were shown to have an expansion in mature
dendritic cells compared to the wild-type mice (110). In this
study, the authors concluded that 1,25(OH)2D3 can
physiologically inhibit dendritic cell maturity even when dendritic
cells are exposed to stimuli that usually control their maturation.
Similar results have been reported in SLE patients (111), where
monocyte-derived dendritic cells responded to 1,25(OH)2D3February 2021 | Volume 11 | Article 616483
Zou et al. Vitamin D Immunomodulation in ARDssupplementation at 10 nM, which led to a shift towards a semi-
mature, tolerogenic phenotype.
Additionally, there is evidence that 1,25(OH)2D3 can inhibit
the expression of IFN-a inducible genes resulting in a reduced
IFN signature response (111). A cross-sectional study found that
25(OH)D levels inversely correlated with serum IFN-a levels (r =
-0.43, p < 0.0001) and IFN-a gene expression (r = -0.45, p <
0.0001) in SLE patients (112). SLE patients with low serum 25
(OH)D levels (≤ 20 ng/ml) overexpressed 2 IFN-a inducible
genes compared to those with sufficient serum levels (≥ 20 ng/
ml) (16). The expression of these two genes was two-fold lower
after cholecalciferol supplementation. However, there are
conflicting results as in a subsequent study, Aranow and
colleagues did not find any improvement of vitamin D
supplementation on IFN signature (113).
1,25(OH)2D3 has also been shown to suppress the
proliferation and differentiation of B cells into memory cells or
plasma cells and induce anti-inflammatory cytokine production
(IL-10) by regulatory B cells (114). Importantly, there is a well-
documented imbalance in these B subsets in SLE patients, with
an increase in plasma cells, which contribute to autoantibody
production, and a defective regulatory B cell compartment (115).
Collectively, these data suggest that the ability of 1,25(OH)2D3 toFrontiers in Immunology | www.frontiersin.org 9skew B cell differentiation in favour of a regulatory phenotype
could be efficacious in suppressing inflammation in SLE patients.
Although there are limited studies investigating whether vitamin
D affects pathogenic mechanisms in SLE, based on the available
evidence in vitro that vitamin D is able to prevent dendritic cell
maturation, inhibit IFN-a production, alter B cell phenotype and
potentially reduce the IFN signature response it is likely to have a
significant impact on the dysregulated immune response. This
represents a serious knowledge gap which should be addressed
with future studies.CONCLUSION
RA, JIA, SLE, and JSLEareARDdrivenbyadysregulated innateand
adaptive immune system. Current treatments aim to control and
relieve the symptoms, as well as prevent long-term damage.
Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids,
disease-modifying anti-rheumatic drugs (DMARDS), and biologic
agents are all part of the therapeutic armamentarium for arthritis
and lupus. Importantly, many of these drugs are associated with
serious side effects such as an increased risk of infection and



















N/A Negative correlation between 25(OH)D levels and SLEDAI and ECLAM scores








29.6 ± 8.8 - patients
30.0 ± 7.0 - controls
N/A Multiple regression analysis showed that 25(OH)D levels associated with SLEDAI
(r = -0.58). 60% of 25(OH)D variation was attributed to SLEDAI.









25(OH)D levels significantly inversely correlated with SLEDAI (b = -0.19; p =
0.003)











25(OH)D levels significantly inversely correlated with SLEDAI-2K (b = -1.1, p =
0.01).
Over 12 months, an increase in vitamin D levels was associated with reduced
disease activity.




95 SLE patients; 40 controls; 8:1
31.54 ± 11.52 patients
31.20 ± 12.97 controls
N/A 25(OH)D was significantly lower in active SLE patients compared to inactive SLE






21 controls, all women
39.6 ± 11.4 patients
40.9 ± 13.3 controls
N/A Fatigue scores were significantly higher (p < 0.0001) and muscle group strengths
were significantly lower in SLE patients than controls.
However, no correlation between fatigue and 25(OH)D levels.
Ruiz-irastorza








Patients with 25(OH)D levels <10 ng/ml had higher but insignificant fatigue
scores than those with >10 ng/ml.








18.9 ± 6.3 patients
17.7 ± 7.4 controls
N/A Patients with active disease had lower 25(OH)D than those with inactive disease.ECLAM score, European Consensus Lupus Activity Measurement score; JSLE, juvenile systemic lupus erythematosus; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus
erythematosus disease activity index; SLEDAI 2K, systemic lupus erythematosus disease activity index 2000 developed as a modification of SLEDAI in order to include persistent, active
disease in those descriptors that had previously only considered new or recurrent occurrences; N/A, not available; 25(OH)D, 25-hydroxy vitamin D.February 2021 | Volume 11 | Article 616483
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unmet need remains for cost-effective therapies with limited
side effects.
Hypovitaminosis D is prevalent among patients with
inflammatory arthritis and SLE across all ages. The majority of
studies have so far provided evidence for an inverse association
between vitamin D levels and disease activity in RA and adult
SLE. The limited number of studies in JIA and JSLE revealed
potential associations between the two, but further research is
required to confirm these results. Since most studies were cross-
sectional, no causal relationship can be inferred, highlighting the
necessity for longitudinal studies that investigate the association
between vitamin D levels and disease activity within the same
patient over time.
In terms of the therapeutic effect of vitaminD supplementation
and suppression of disease activity, randomized controlled trials
have yet to provide evidence for its efficacy in both diseases.
Notably, the studies included in this review have exposed several
limitations of the research on this topic. One prominent problem
lies in the high heterogeneity between studies regarding the
subject population, vitamin D supplementation dose and
frequency of administration, outcome measurements, and even
definitions of vitamin D deficiency. Trials have been conductedFrontiers in Immunology | www.frontiersin.org 10in over 20 countries in various continents, and many found that
the prevalence of low vitamin D levels varied geographically,
which could be due to differences related to ethnic background,
sun exposure, and clothing style. Developmental status of the
country, which significantly influences the quality of diet, and
therefore vitamin D intake, will also affect vitamin D levels. In
addition, the studies investigating the impact of vitamin D
supplementation on the risk of developing arthritis or SLE are
limited by the use of self-reported and retrospective data.
Furthermore, the lack of consensus in dosage regimens between
different studies in both RA and SLE means that there is no
conclusive evidence of the role of vitamin D supplementation on
disease outcomes.
Nevertheless, immunomodulatory studies have offered
promising results. In vitro addition of 1,25(OH)2D3 altered the
phenotype of dendritic cells, shifted the balance of T helper cells,
inhibited pro-inflammatory cytokines and interferon proteins
production, and subsequently affected both T and B cell activity,
which could be relevant for the pathogenesis of both RA and SLE.
Importantly, the wide-ranging effects of vitamin D on potential
pathogenic pathways highlights a potentia l potent
immunosuppressive function in these diseases, if the right
therapeutic protocol is identified.TABLE 5 | Impact of vitamin D supplementation on JSLE and adult-onset SLE outcomes.
Author et al., year Country Type of
study Study duration
Number of patients vs. control
group (if any) F:M Age (mean
+/- SD)
Vitamin D dose Impact on disease activity
Adult-onset SLE









Standard regimen (25,000 IU vit D3
monthly for one year) then intensive
regiment (300,000 IU initial bolus then
50,000 IU a second year), or vice versa
No significant difference in disease






12 weeks and 3
months
45 SLE patients in intervention
arm vs. 45 in placebo arm
9:1
33.78 ± 6.2 vs. 35.69 ± 6.8
50,000 IU/week vit D3 for 12 weeks then
50,000 IU/month for 3 months
No significant difference in SLEDAI in
intervention group and placebo
group.




763 SLE patients with




Ergocalciferol 50,000 IU/week and 200 IU
of calcium/D3 twice daily
Patients with supplementation had a
20 unit increase in 25(OH)D and 21%
decrease in the odds of having a high










Varying dosage of oral vit D3 400–1,200
IU/day for 7–24 months
No significant correlations between
change in SLEDAI and change in 25
(OH)D levels








100,000 IU/week vit D3 for 4 weeks, then
100,000 IU/month vit D3 for 6 months
No significant change in SLEDAI







Varying vit D3 supplementation No significant difference in SLEDAI
scores.
JSLE








2,000 IU/daily vit D3 An inverse correlation between 25
(OH)D and SLEDAI was observed,
but it was not statistically significant.
Lima et al., 2016 (95) Brazil
RCT
6 months
20 treatment vs 20 placebo
All female
18.5 ± 3.5 vs 19.3 ± 3.3
75
50,000 IU/week vit D3 A significantly decrease in SLEDAI
and fatigue severity score.FebruaJSLE, juvenile systemic lupus erythematosus; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; 25(OH)D, 25-hydroxy vitamin D.ry 2021 | Volume 11 | Article 616483
Zou et al. Vitamin D Immunomodulation in ARDsAlthough the scope of this review was to specifically explore the
immunomodulatory role of vitamin D in arthritis and lupus across
age, there is evidence of its benefits in other ARDs, such as
undifferentiated connective tissue disease (UCTD). A 5-week
course of daily alfacalcidol supplementation at various doses
administered in two open label trials to patients with UCTD
restored the capacity of regulatory T cells to suppress the
proliferation of autologous CD4+ T cells implicated in the
pathogenesis of the disease (116, 117), providing evidence for a
potential therapeutic role of vitamin D in the management of this
condition. A large study of 1,029 patients with various ARDs,
including RA, SLE, autoimmune myositis, scleroderma,
antiphospholipid syndrome, multiple sclerosis, and autoimmune
thyroid disease, measured the serum vitamin D levels using an
immunoluminometric assays and found suboptimal levels (< 20ng/
ml) in all patients (118). This study found no correlation between
vitamin D level and SLE disease activity measured using the
ECLAM score. Overcoming the limitations of available research
in this field would close the gap between hypothesis and treatment
efficacy. Future research should focus on large randomized,
controlled trials that investigate different doses of vitamin D
supplementation at different frequencies of administration, which
should also include adequate stratification of patients based on age,
disease activity and background medication. The future calls forFrontiers in Immunology | www.frontiersin.org 11better designed research including appropriate collection of
metadata which allows confounders to be built into multivariate
regression models that allow a better understanding of the
relationship between vitamin D levels and disease outcomes. To
help reduce the study heterogeneity, a clear definition for vitaminD
deficiency/insufficiency should be agreed on for both adults and
children. Further recommendations for clinical practice should be
guided by good quality evidence of the impact of vitamin D
supplementation on disease outcomes, as well as additional health
benefits (related or unrelated to the underlying ARD). If beneficial,
vitamin D has the advantage of being a relatively cheap and
relatively safe treatment option. In conclusion, although the level
of evidence for the benefits of vitamin D supplementation on
outcome measures in arthritis and SLE across ages is poor, the
hypothesis of a potential role of vitaminD as an adjuvant treatment
option for these diseases remains promising based on available
immunological data, but requires further research.AUTHOR CONTRIBUTIONS
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